Boston Scientific (BSX) PT Raised to $23.50 at Evercore ISI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Boston Scientific (BSX) PT Raised to $26 at Needham & Company
April 27, 2016 2:13 PM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and boosted his price target on Boston Scientific (NYSE: BSX) to $26.00 (from $22.00), saying Q1 marks and inflection point for growth and margins.
Matson commented, "BSX beat consensus 1Q16 revenue and EPS by a wide margin.... More
Boston Scientific (BSX) Gains Following Strong Results, Outlook
April 27, 2016 9:53 AM EDTBoston Scientific (NYSE: BSX) is strong out of the gate following better-than-expected earnings and a raised outlook. Shares last traded up 8.9%.
Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.28, $0.04 better than the analyst estimate of $0.24. Revenue for the... More
Boston Scientific (BSX) Tops Q1 EPS by 4c; Boosts FY16 Outlook
April 27, 2016 6:32 AM EDTBoston Scientific (NYSE: BSX) reported Q1 EPS of $0.28, $0.04 better than the analyst estimate of $0.24. Revenue for the quarter came in at $1.96 billion versus the consensus estimate of $1.91 billion.
GUIDANCE:
Boston Scientific sees Q2 2016 EPS of $0.25-$0.27, versus the consensus of $0.26.... More
